Giuseppe
Emeritus
[Source: Eurosurveillance, full text: (LINK). Abstract, edited.]
D M Skowronski (
)<SUP>1</SUP><SUP>,2</SUP>, N Z Janjua<SUP>1</SUP><SUP>,2</SUP>, G De Serres<SUP>3</SUP><SUP>,4</SUP><SUP>,5</SUP>, J A Dickinson<SUP>6</SUP>, A-L Winter<SUP>7</SUP>, S M Mahmud<SUP>8</SUP><SUP>,9</SUP>, S Sabaiduc<SUP>1</SUP>, J B Gubbay<SUP>7</SUP><SUP>,10</SUP>, H Charest<SUP>3</SUP>, M Petric<SUP>1</SUP><SUP>,2</SUP>, K Fonseca<SUP>6</SUP><SUP>,11</SUP>, P Van Caeseele<SUP>12</SUP>, T L Kwindt<SUP>1</SUP><SUP>,2</SUP>, M Krajden<SUP>1</SUP><SUP>,2</SUP>, A Eshaghi<SUP>7</SUP>, Y Li<SUP>9</SUP><SUP>,13</SUP>
Citation style for this article: Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter A, Mahmud SM, Sabaiduc S, Gubbay JB, Charest H, Petric M, Fonseca K, Van Caeseele P, Kwindt TL, Krajden M, Eshaghi A, Li Y. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada?s sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5)
ii=20394. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394
Date of submission: 21 January 2013 <HR>The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada?s sentinel surveillance network using a test-negative case?control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13?66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene.
- ------
Eurosurveillance, Volume 18, Issue 5, 31 January 2013
Rapid communications
Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada?s sentinel surveillance network, January 2013
Rapid communications
Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada?s sentinel surveillance network, January 2013
D M Skowronski (
- British Columbia Centre for Disease Control, Vancouver, Canada
- University of British Columbia, Vancouver, Canada
- Institut National de Sant? Publique du Qu?bec (National Institute of Health of Quebec), Qu?bec, Canada
- Laval University, Quebec, Canada
- Centre Hospitalier Universitaire de Qu?bec (University Hospital Centre of Quebec), Qu?bec, Canada
- University of Calgary, Calgary, Canada
- Public Health Ontario, Toronto, Canada
- Winnipeg Regional Health Authority, Winnipeg, Canada
- University of Manitoba, Winnipeg, Canada
- University of Toronto, Toronto, Canada
- Alberta Provincial Laboratory, Calgary, Canada
- Cadham Provincial Laboratory, Winnipeg, Canada
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
Citation style for this article: Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter A, Mahmud SM, Sabaiduc S, Gubbay JB, Charest H, Petric M, Fonseca K, Van Caeseele P, Kwindt TL, Krajden M, Eshaghi A, Li Y. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada?s sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5)
ii=20394. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394 Date of submission: 21 January 2013 <HR>The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada?s sentinel surveillance network using a test-negative case?control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13?66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene.